Member Info for inanaco

Ask you some questions ..

why did Roche and BioNtech fail to get great responses from an MRNA personal vaccine ... targeting up to 20 individual neo Antigens considering the combined Mcap probably exceeds $300 billion do you think the share price played a part ? because that is what you are fussing over ....

yes we should advise MHRA and the FDA ... that Scancell has developed the Tits Up approach ... apparently using Viagra in this way may further inflame womans rights movements ..

52-wk high 33.79
52-wk low 1.92

erh .... he has blown how much ?

$700m ? on development .. off ....

Take the Knee bermuda ... and join in ..... the old buggers matter ..

well ......... 50% could be the young .........and i am sure the other 50% could be the old .........

useful ... ?

well i hope you like the odds ............ 50/50 ............... use the vaccine but ...

The guidance also discusses the importance of ensuring that the sizes of clinical trials are large enough to demonstrate the safety and effectiveness of a vaccine. It conveys that the FDA would expect that a COVID-19 vaccine would prevent disease or decrease its severity in at least 50% of people who are vaccinated.

Additionally, after approval by the FDA, the safety of all vaccines, including a COVID-19 vaccine, continues to be closely monitored using various existing surveillance systems. The FDA may also require post-marketing studies to further assess known or potential serious risks.

The guidance also notes that, as more is learned about SARS-CoV-2 immunology and vaccine immune responses, consideration may be given to the FDA’s Accelerated Approval pathway for vaccine licensure. However, identification of an immune response or other measure that is reasonably likely to predict clinical benefit would be needed for a specific vaccine candidate to use of this pathway. Due to the current public health emergency, the guidance also addresses considerations regarding Emergency Use Authorization (EUA) of an investigational vaccine – making clear that an assessment regarding any potential EUA for a COVID-19 vaccine would be made on a case-by-case basis considering the target population, the characteristics of the product, and the totality of the relevant, available scientific evidence, including preclinical and human clinical study data on the product’s safety and effectiveness.

For Immediate Release:
June 30, 2020
Today, the U.S. Food and Drug Administration took important action to help facilitate the timely development of safe and effective vaccines to prevent COVID-19 by providing guidance with recommendations for those developing COVID-19 vaccines for the ultimate purpose of licensure. The guidance, which reflects advice the FDA has been providing over the past several months to companies, researchers, and others, describes the agency’s current recommendations regarding the data needed to facilitate the manufacturing, clinical development, and approval of a COVID-19 vaccine

well .. its rare that i post .. I don't know .. LOL

and off course what effects is no surgery having on melanoma patients .......................... and for that mater lung cancer patients

I really don't know ......... all depends from a Business perspective if you feel a second wave could cause you difficulty and what steps the investigator can take to make sure the trial is completed regardless, then you have the fear factor of those patients currently isolated actually attending or even considering a trial in this environment .

should have added reading Patents as well ........

In fairness Ivy .. you should never compare why people invest as they do ... Scancell is a Research led "invention machine" requiring a serious understanding, and if you are going to run big numbers for the Golden Ticket.. you not only need to understand scancell but also the market it sits in, which means constant reading of research papers

Indeed Diggles did not go in Cold ... instead he sent his science team in first ...

which is why any positive decision .. is better than a dithering position

so you re not in .... Nom ..

Thanks for the update

oh no ... not another Maths history lesson .. ref sub 4p buys ?

referee ... not a course ... but being able to study history helps ..

perfect example ........... The £10 share

Look ... Ivy gave his reasons ... and sold up ......... Good for him ... Positive move .. his decision .. no objection at all from me

however ... his sold shares now belong to somebody else ........ Ivy has been replaced

he thinks the opposite to Ivy ....

balance

nobody is stopping you Nom ...

Ivy you held far higher than the current SP .. the fact that you didn't declare your buys sub 4p means you cannot declare them now as a means of hiding a loss from a way higher number ...
you have posted since 2015 ... not 2012 .. which was the initial .... 6p to 8p range